Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2008-07-15
2010-11-09
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C435S320100
Reexamination Certificate
active
07829078
ABSTRACT:
The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.
REFERENCES:
patent: 5252479 (1993-10-01), Srivastava
patent: 5589362 (1996-12-01), Bujard et al.
patent: 5658565 (1997-08-01), Billiar et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5858351 (1999-01-01), Podsakoff et al.
patent: 6162796 (2000-12-01), Kaplitt et al.
patent: 6211163 (2001-04-01), Podsakoff
patent: 6325998 (2001-12-01), Podsakoff
patent: 6335011 (2002-01-01), Podsakoff
patent: 6391858 (2002-05-01), Podsakoff
patent: 6610290 (2003-08-01), Podsakoff et al.
patent: 7238674 (2007-07-01), Podsakoff et al.
patent: WO 94/13788 (1994-06-01), None
patent: WO 95/13376 (1995-05-01), None
patent: WO 95/20671 (1995-08-01), None
patent: WO 95/28493 (1995-10-01), None
patent: WO 95/34670 (1995-12-01), None
patent: WO 96/00006 (1996-01-01), None
patent: WO 96/14061 (1996-05-01), None
patent: WO 96/40272 (1996-12-01), None
patent: WO 97/12050 (1997-04-01), None
Acsadi, et al., “Human Dystrophin Expression in Mdx Mice After Intramuscular Injection of DNA Constructs,”Nature352:815-818 (1991).
Acsadi, et al., “Cultured Human Myoblasts and Myotubes Show Markedly Different Transducibility by Replication-Defective Adenovirus Recombinants,”Gene Ther1:338-340 (1994).
Acsadi, et al., A Different Efficiency of Adenovirus-Mediated in Vivo Gene Transfer into Skeletal Muscle Cells of Different Maturity,Hum Mol Genetics3:579-584 (1994).
Barr and Leiden, “Systematic Delivery of Recombinant Proteins by Genetically Modified Myoblasts,”Science254:1507-1509 (1991).
Bartlett, et al.,Am J Hum Genet57(4):#A235 (1995).
Blau and Springer, “Molecular Medicine Muscle-Mediated Gene Therapy,”New Engl J Med333:1204-1207 (1995).
Blau and Springer, “Molecular Medicine Gene Therapy—A Novel Form of Drug Delivery,”New Engl J Med333:1554-1556 (1995).
Dai, et al., “Gene Therapy Via Primary Myoblasts: Long-Term Expression of Factor Ix Protein Following Transplantation in Vitro,”PNAS USA89:10892-10895 (1992).
Dai, et al., “Cellular and Humoral Immune Responses to Adenoviral Vectors Containing Factor Ix Gene: Tolerization of Factor Ix and Vector Antigens Allows for Long-Term Expression,”PNAS USA92:1401-1405 (1995).
Davis, et al., “Direct Gene Transfer Into Skeletal Muscle in Vivo: Factors Affecting Efficiency of Transfer and Stability of Expression,”Hum Gene Ther4:151-159 (1993).
Descamps, et al., “Organoids Direct Systematic Expression of Erythropoietun in Mice,”Gene Therapy2:411-417 (1995).
Dhawan, et al., “Systematic Delivery of Human Growth Hormone by Injection of Genetically Engineered Myoblasts,”Science254:1509-1512 (1991).
Flotte, et al., “Gene Expression From Adeno-Associated Virus Vectors in Airway Epithelial Cells,”Am J Respir Cell Mol Biol7:349-356 (1992).
Flotte, et al., “Expression of the Cystic Fibrosis Transmembrane Conductance Regulator from a Novel Adeno-Associated Virus Promoter,”J Biol Chem268:3781-3790 (1993).
Flotte, et al., “Stable In Vivo Expression of the Cystic Fibrosis Transmembrane Conductance Regulator with an Adeno-Associated Virus Vector,”PNAS USA90:10613-10617 (1993).
Flotte, et al., “Adeno-Associated Virus Vector Gene Expression Occurs in Non-Dividing Cells in the Absence of Vector DNA Integration,”Am J Respir Cell Mol Biol11:517-521 (1994).
Gilgenkrantz, et al., “Transient Expression of Genes Transferred In Vivo Into Heart Using First-Generation Adenoviral Vectors: Role of the Immune Response,”Hum Gene Ther6:1265-1274 (1995).
Hamamori, et al., “Persistant Erythropoiesis by Myoblast Transfer of Erythropoietin cDNA,”Hum Gene Ther5:1349-1356 (1994).
Hamamori, et. al., “Myoblast Transfer of Human Erythropoietin Gene in a Mouse Model of Renal Failure,”J. CLin Invest95:1808-1813 (1995).
Herzog, et al., “Stable Gene Transfer and Expression of Human Blood Coagulation Factor IX After Intramuscular Injection of Recombinant Adeno-Associated Virus,”PNAS USA94:5804-5809 (1997).
Kaplitt, et al., “Long-Term Gene Expression and Phenotypeic Correction Using Adeno-Associated Virus Vectors in the Mammalian Brain,”Nat Genet8:148-154 (1994).
Kessler, et al., “Gene Delivery to Skeletal Muscle Results in Sustained Expression and Systematic Delivery of Therapeutic Protein,”PNAS USA93:14082-14087 (1996).
Kessler, et al., Gene Delivery to 1,2,4,5 Skeletal Muscle Results in Sustained Expression and Systematic Delivery of a Therapeutic Protein,PNAS USA93:14082-14087 (1996).
Knowles, et al., “A Controlled Study of Adenoviral-Vector-Mediated Gene Transfer in the Nasal Epithelium of Patients with Cystic Fibrosis,”New Engl J Med333(13):823-831 (1995).
Kotin, “Prospects for the Use of Adeno-Associated Virus as a Vector for Human Gene Therapy,”Hum Gene Ther5:793-801 (1994).
Leiden, “Gene Therapy-Promise, Pitfalls and Prognisis,”New Engl J Med333:871-872 (1995).
March, et al.,Clin Res40(2):358A (1992).
Mendell, et al., “Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy,”New Engl J Med333:832-838 (1995).
Naffak, et al., “Sustained Delivery of Erythropoietin in Mice by Genetically Modified Skin Fibroblasts,”PNAS92:3194-3198 (1995).
Naffak, et al., “Long-Term Secretion of Therapeutic Proteins from Genetically Modified Skeletal Muscles,”Hum Gene Ther7:11-21 (1996).
Osborne, et al., “Gene Therapy for Long-Term Expression of Erythropoietin in Rats,”PNAS92:8055-8058 (1995).
Podsakoff, et al., “AAV Vector-Mediated Gene Delivery to Skeletal Muscle in Vivo Results in Sustained Levels of Systematic Erythropoietin,”Blood88(10):1066 (1996).
Podsakoff, et al., Efficient Gene Transfer Into Non-Dividing Cells by Adeno-Associated Virus Based Vectors,J Virol68:5656-5666 (1994).
Podsakoff, et al., Long Term in Vivo Gene Expression in Muscle Using AAV Vectors,Blood86(10):1004A 91995).
Quantin, et al., “Adenovirus as an Expression Vector in Muscle Cells In Vivo,”PNAS USA89:2581-2584 (1992).
Raz, et al., “Systematic Immunological Effects of Cytokine Genes Injected into Skeletal Muscle,”PNAS USA90:4523-4527 (1993).
Russell, et al., “Adeno-Associated Virus Vectors Preferentially Transduce Cells in S Phase,”PNAS USA91:8915-8919 (1994).
Snyder, et al., “Persistant and Therapeutic Concentrations of Human Factor IX in Mice After Hepatic Gene Transfer of Recombinant AAV Vectors,”Nature Genet16:270-276 (1997).
Tripathy, et al., “Stable Delivery of Physiologic Levels of Recombinant Erythropoietin to the Systematic Circulation by Intramuscular Injection of Replication-Defective Adenovirus,”PNAS USA91:11557-11561 (1994).
Villeval, et al., “Retrovirus-Medicated Transfer of the Eurythropoietin Gene in Hematopoietic Cells Improves the Erythrocyte Phenotype in Murine B-Thalassemia,”Blood84(3):928-933 (1994).
Wolff, et al., “Direct Gene Transfer Into Mouse Muscle in Vivo,”Science247:1465-1468 (1990).
Wolff, et al., “Long Term Persistence of Plasmid DNA and Foreign Gene Expression in Mouse Muscle,”Hum Mol Genet1:363-369 (1992).
Xiao, et al., “Adeno-Associated Virus (AAV) Vectors for Gene Transfer,”Adv Drug Del Rev12:201-215 (1993).
Xiao, et al., “Efficient Long-Term Gene Tr
Byrne Barry J.
Kessler Paul D.
Kurtzman Gary J.
Podsakoff Gregory M.
Crouch Deborah
Genzyme Corporation
Johns Hopkins University
Robins Roberta L.
Robins & Pasternak LLP
LandOfFree
Methods of treating anemia using recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating anemia using recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating anemia using recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4213345